Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,768
datasets available to search
ShareScore release 0.9.0
Dataset results
1,768 results for “beta cell”
A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function
ClinicalTrials.gov study NCT02443155. IPD Sharing: Not stated. Countries: 18. Publications: 1.
DPP4 Inhibition & Beta Cell Function
ClinicalTrials.gov study NCT02683187. IPD Sharing: Not stated. Countries: 1. Publications: 1.
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia
ClinicalTrials.gov study NCT02604433. IPD Sharing: Not stated. Countries: 15. Publications: 7.
Mechanism Underlying Beta-cell Failure in Obese African Americans With History of Hyperglycemic Crises
ClinicalTrials.gov study NCT00753142. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
ClinicalTrials.gov study NCT01851694. IPD Sharing: YES. Countries: 1. Publications: 1.
Immune Intervention With Rituximab to Preserve Beta Cell Function in Early Onset Type 1 Diabetes
ClinicalTrials.gov study NCT01280682. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists
ClinicalTrials.gov study NCT07325435. IPD Sharing: NO. Countries: 1. Publications: 11.
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
ClinicalTrials.gov study NCT02846545. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes
ClinicalTrials.gov study NCT04233034. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Beta-Cell Function and Sitagliptin Trial (BEST)
ClinicalTrials.gov study NCT00420511. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant (Haplo SCT)
ClinicalTrials.gov study NCT02193880. IPD Sharing: NO. Countries: 1. Publications: 33.
Combination Therapy With Sitagliptin and Lansoprazole to Restore Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes
ClinicalTrials.gov study NCT01155284. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Effect of Prebiotics on the Gut Microbiome Profile and Beta Cell Function
ClinicalTrials.gov study NCT04114357. IPD Sharing: NO. Countries: 1. Publications: 1.
Novel Therapy to Preserve Beta Cell Function in New Onset Type 1 Diabetes
ClinicalTrials.gov study NCT00837759. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Insulin Sensitivity and Beta Cell Function After Carbohydrate Loading in Hip Replacement Surgery
ClinicalTrials.gov study NCT01774084. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Preservation of Beta-cell Function in Type 2 Diabetes Mellitus
ClinicalTrials.gov study NCT00232583. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure
ClinicalTrials.gov study NCT02105766. IPD Sharing: YES. Countries: 1. Publications: 2.
Effect of Pioglitazone and Exenatide on Body Weight and Beta Cell Function
ClinicalTrials.gov study NCT00845182. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Effect of the Anti-oxidant N-acetylcysteine on Beta-cell Function in Type 2 Diabetes
ClinicalTrials.gov study NCT01394510. IPD Sharing: NO. Countries: 1. Publications: 1.
Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes
<p><span><b>Context:</b> Novel dual GIP and GLP-1 receptor agonist (RA) tirzepatide demonstrated substantially greater glucose control and weight loss (WL) compared with selective GLP-1RA dulaglutide.</span></p> <p><span><b>Objective:</b> Explore mechanisms of glucose control by tirzepatide. </span></p> <p><span><b>Design:</b> <i>Post-hoc</i> analyses of fasting biomarkers and multiple linear regression analysis.</span></p> <p><span><b>Setting:</b> 47 sites in 4 countries.</span></p> <p><span><b>Patients or Other Participants:</b> 316 subjects with Type 2 diabetes.</span></p> <p><span><b>Interventions:</b> Tirzepatide (1, 5, 10, 15 mg), dulaglutide (1.5 mg), placebo. </span></p> <p><span><b>Main Outcome Measures:</b> Analyze biomarkers of beta-cell function and insulin resistance (IR) and evaluate WL contributions to IR improvements at 26 weeks. </span></p> <p><span><b>Results:</b> HOMA2-B significantly increased with dulaglutide and tirzepatide 5, 10, and 15 mg compared with placebo (p<u><</u>0.02). Proinsulin/insulin and proinsulin/C-peptide ratios significantly decreased with tirzepatide 10 and 15 mg compared with placebo and dulaglutide (p<u><</u>0.007). Tirzepatide 10 and 15 mg significantly decreased fasting insulin (p<u><</u>0.033) and tirzepatide 10 mg significantly decreased HOMA2-IR (p=0.004) compared with placebo and dulaglutide. Markers of improved insulin sensitivity (IS) adiponectin, IGFBP-1, and IGFBP-2 significantly increased by one or more doses of tirzepatide (p<0.05). To determine whether improvements in IR were directly attributable to WL, multiple linear regression analysis with potential confounding variables age, sex, metformin, triglycerides, and HbA1c was conducted. WL significantly (p<u><</u>0.028) explained only 13% and 21% of improvement in HOMA2-IR with tirzepatide 10 and 15 mg, respectively. </span></p> <p><span><b>Conclusions:</b> Tirzepatide improved markers of IS and beta-cell function to a greater extent than dulaglutide. IS effects of tirzepatide were only partly attributable to WL, suggesting dual receptor agonism confers distinct mechanisms of glycemic control.</span></p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.